| Literature DB >> 36076062 |
Makoto Horikawa1, Shinichiro Koizumi1, Tomoya Oishi1, Taisuke Yamamoto1, Masashi Ikeno2, Masahiko Ito3, Tomohiro Yamasaki1, Shinji Amano4, Tetsuro Sameshima1, Yasuyuki Mitani5, Yoshihiro Otani6, Yuanqing Yan7, Tetsuro Suzuki3, Hiroki Namba8, Kazuhiko Kurozumi9.
Abstract
Herpes simplex virus thymidine kinase (HSVTK)/ganciclovir (GCV) suicide gene therapy has a long history of treating malignant gliomas. Recently, stem cells from human exfoliated deciduous teeth (SHED), which are collected from deciduous teeth and have excellent harvestability, ethical aspects, and self-renewal, have been attracting attention mainly in the field of gene therapy. In the present study, we assessed SHED as a novel cellular vehicle for suicide gene therapy in malignant gliomas, as we have previously demonstrated with various cell types. SHED was transduced with the HSVTK gene (SHEDTK). In vitro experiments showed a significant bystander effect between SHEDTK and glioma cell lines in coculture. Furthermore, apoptotic changes caused by caspase 3/7 activation were simultaneously observed in SHEDTK and glioma cells. Mice implanted with a mixture of U87 and SHEDTK and treated with intraperitoneal GCV survived for longer than 100 days. Additionally, tumors in treatment model mice were significantly reduced in size during the treatment period. SHEDTK implanted at the contralateral hemisphere migrated toward the tumor crossing the corpus callosum. These results suggested that SHEDTK-based suicide gene therapy has potent tumor tropism and a bystander-killing effect, potentially offering a new promising therapeutic modality for malignant gliomas.Entities:
Year: 2022 PMID: 36076062 DOI: 10.1038/s41417-022-00527-5
Source DB: PubMed Journal: Cancer Gene Ther ISSN: 0929-1903 Impact factor: 5.854